论文部分内容阅读
目的宫颈癌术前行新辅助化疗的临床疗效。方法选取2008—2014年于中国人民解放军第515医院治疗的宫颈癌患者60例,根据患者术前是否进行新辅助化疗分成对照组和观察组,各30例。对照组直接进行手术,观察组在术前接受新辅助化疗,比较两组患者的临床疗效。结果观察组化疗前后肿瘤直径大小比较,差异有统计学意义(P<0.01)。观察组患者手术时间短于对照组、术中出血量少于对照组、淋巴脉管受累率及淋巴结转移率低于对照组,总有效率高于对照组,差异有统计学意义(P<0.05)。结论宫颈癌术前新辅助化疗能够缩小肿瘤体积,改善手术治疗的条件,有利于进行肿瘤切除,提高手术安全性,临床疗效显著。
Objective To evaluate the clinical effect of neoadjuvant chemotherapy in preoperative cervical cancer. Methods Sixty patients with cervical cancer who were treated in Chinese People’s Liberation Army No. 515 Hospital from 2008 to 2014 were selected and divided into control group and observation group according to whether the patients received neoadjuvant chemotherapy preoperatively and 30 patients in each group. The control group was operated directly. The observation group received neoadjuvant chemotherapy before surgery, and the clinical efficacy of the two groups was compared. Results Before and after chemotherapy, the diameter of tumor in the observation group was significantly different (P <0.01). The operation time of the observation group was shorter than that of the control group, the blood loss was less than the control group, the rate of lymph vessel involvement and lymph node metastasis was lower than that of the control group, the total effective rate was higher than that of the control group (P <0.05 ). Conclusion Neoadjuvant chemotherapy before cervical cancer can reduce the tumor volume and improve the surgical treatment conditions, is conducive to tumor resection and improve the safety of surgery, clinical efficacy significantly.